Dr. Salvatore Del Prete has cared for patients with cancer at Stamford Health since 1984.
As director of clinical trials at the Bennett Cancer Center, Dr. Del Prete leads a robust program that includes advanced clinical research and national trials for many diseases. His goal is to offer his patients the latest clinical trial treatments for any stage of cancer so that they can choose to participate in trials without leaving the area.
Dr. Del Prete has been especially interested in treating melanoma since medical school, when he worked at Roswell Park Cancer Institute. While at Dartmouth-Hitchcock, he was also involved in and was the lead author of the Dartmouth regimen for melanoma patients. Since then, he has participated in multiple melanoma clinical trials, including the trials for the immunotherapies now available.
Dr. Del Prete is also very interested in caring for all types of lung and gynecologic cancer. He has been a major part of the gynecologic cancer team since 1985, and was the first researcher to study the initial use of intraperitoneal chemotherapy in patients with ovarian cancer who hadn’t received chemotherapy. This treatment is now the top standard of care for those women. Similarly, in lung cancer treatment, he was one of the first oncologists to use combined radiation therapy and chemotherapy, which is now the standard of care for that condition.
Dr. Del Prete believes that the future of cancer care is bright. Thanks to innovative research and clinical trials, treatments are beginning to meet all his patients’ needs.